US2022175703A1PendingUtilityA1
Compositions and Methods of Achieving Pain Relief
Est. expiryJun 20, 2037(~10.9 yrs left)· nominal 20-yr term from priority
A61K 31/164A61K 31/16A61K 31/015A61K 31/045A61P 23/02
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
In one aspect, this invention relates to a method for treating pain and subsequent resulting conditions. In yet another aspect, this invention relates to formulating agents to rapidly reverse painful conditions.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating a subject in need of pain relief by administering to a subject an effective pain-relieving amount of a composition comprising a mixture of spilanthol, pellitorine, beta-caryophyllene and pro-vitamin B5.
2 . The method of claim 1 , where the composition further contains menthol.
3 . The method of claim 1 , wherein the painful condition is caused by or related to a body condition selected from the group consisting of: Chronic and Acute Pain of the muscles, joints and ligaments, Migraine Headaches, Diabetes, Arteriosclerosis, Radiation Dermatitis, Pruritus, Insect bites, Anaphylactic Shock from serious allergic responses to allergens from Insect Bites, Food Allergies, Pollens and other Environmentally induced allergies, Carbuncles, Acne, Dermal burns due to exposure to sun, x-rays and/or excessive heat, Cancer, Mucositis, Aphthous ulcers, Periodontal and Gingivitis disease, Herpes simplex, Herpes zoster, Coronavirus-19, Yeast and/or Microbial infections, Psoriasis, Crohn's disease, Lupus, painful scarring, Irritable Bowel disease, other Autoimmune Diseases and Diseases causally related to autoimmune diseases like fibromyalgia, Rheumatoid and Osteoarthritis, and Xerostomia.
4 . The method of claim 1 , wherein said composition is administered to the subject by a route selected from the group consisting of mucosal, dermal, oral, inhalation, injection, nasal, and other common routes known in the medical arts.
5 . The method of claim 1 , wherein the painful conditions are controlled by affecting one or more biochemical control systems selected from the group consisting of Annexin A1, NRF2, NFkB, PI3K, AKT, p38-MAPK, JNK, PIP2, PIP3, ERK1/2, cAMP, Adenylyl cyclase, TRPV1, TRPA1, TRPM8, PGE2, IL-1b, CXCR4, CXCL12 and CB2.
6 . The method of claim 1 , wherein the non-vitamin components of the mixture are administered in an amount of from 0.01 mg to 1000 mg per dose.
7 . The method of claim 1 , wherein the vitamin component is administered at from 1.5 mg to 1000 mg per dose.
8 . The method of claim 1 , wherein the vitamin component is administered at from 2.5 mg to 500 mg per dose.
9 . A pain relief composition comprising a mixture of spilanthol, pellitorine, beta-caryophyllene and pro-vitamin B5.
10 . The composition of claim 9 , wherein the composition is useful for oral use, and the mixture includes from 0.0025 wt % to 0.4 wt % spilanthol and 0.0015 wt % to 0.2 wt % pellitorine.
11 . The composition of claim 10 , wherein the pro-vitamin B5 is present at from 0.1 wt % to 0.5 wt %.
12 . The composition of claim 10 , which further includes menthol at from 0.0005 wt % to 0.005 wt %.
13 . The composition of claim 9 , wherein the composition is useful for skin treatment, and the mixture includes spilanthol at 0.1 wt % to 0.5% wt %, pellitorine at 0.05 wt % to 0.2 wt % and beta-caryophyllene at 1 wt % to 3 wt %.
14 . The composition of claim 13 , wherein the pro-vitamin B5 is present at from 2 wt % to 6 wt %.
15 . The composition of claim 13 , which further includes menthol at from 0.02 wt % to 3 wt %.
16 . The composition of claim 9 , wherein the composition is useful for joint pain, and the mixture includes spilanthol and pellitorine, each at from 0.05 wt % to 0.3 wt %, and beta-caryophyllene at from 1 wt % to 3 wt %.
17 . The composition of claim 16 , wherein the pro-vitamin B5 is present at from 1.0 wt % to 6.0 wt %.
18 . The composition of claim 16 , which further includes menthol at from 0.1 wt % to 3 wt %.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.